Neuron-specific-enolase as a predictor of the neurologic outcome after cardiopulmonary resuscitation in patients on ECMO.


Journal

Resuscitation
ISSN: 1873-1570
Titre abrégé: Resuscitation
Pays: Ireland
ID NLM: 0332173

Informations de publication

Date de publication:
03 2019
Historique:
received: 19 10 2018
revised: 22 12 2018
accepted: 06 01 2019
pubmed: 18 1 2019
medline: 2 5 2020
entrez: 18 1 2019
Statut: ppublish

Résumé

Neuron-specific-enolase (NSE) is frequently used to predict the neurologic outcome in persistently unconscious patients after cardiopulmonary resuscitation (CPR). However, its predictive value is unclear in the setting of veno-arterial extracorporeal membrane oxygenation therapy (ECMO). Aim of this project is to evaluate the predictive value of NSE in ECMO patients. NSE was measured after 24, 48, and 72 h in post-CPR ECMO patients. Neurologic status was evaluated using the best Cerebral Performance Categories Score (CPC) during the hospital stay. Patients who deceased within the first 24 h and patients who were awake during the first 24 h were excluded. ROC curves were calculated to assess the discriminative ability of single NSE measurements. Trajectories of serial NSE values were investigated using latent class mixed models. The derivation cohort consisted of 65 patients, 30-day all-cause mortality was 47.7% and a poor neurological outcome with a CPC score of 4-5 was seen 30.7%. NSE measurement after 48 h showed the best discrimination for poor neurological outcome (AUC of 0.87 in the ROC curve; cut-off value of 70 μg/L). Specificity was highest if using serial NSE measurements at all three time points. These results could be validated in an external cohort of 64 patients. In post-CPR patients on ECMO, NSE can be used to assess the neurologic outcome. Importantly, specificity was highest if using serial NSE measurements. Further research using prospective datasets is needed to verify these findings.

Sections du résumé

BACKGROUND
Neuron-specific-enolase (NSE) is frequently used to predict the neurologic outcome in persistently unconscious patients after cardiopulmonary resuscitation (CPR). However, its predictive value is unclear in the setting of veno-arterial extracorporeal membrane oxygenation therapy (ECMO). Aim of this project is to evaluate the predictive value of NSE in ECMO patients.
METHODS
NSE was measured after 24, 48, and 72 h in post-CPR ECMO patients. Neurologic status was evaluated using the best Cerebral Performance Categories Score (CPC) during the hospital stay. Patients who deceased within the first 24 h and patients who were awake during the first 24 h were excluded. ROC curves were calculated to assess the discriminative ability of single NSE measurements. Trajectories of serial NSE values were investigated using latent class mixed models.
RESULTS
The derivation cohort consisted of 65 patients, 30-day all-cause mortality was 47.7% and a poor neurological outcome with a CPC score of 4-5 was seen 30.7%. NSE measurement after 48 h showed the best discrimination for poor neurological outcome (AUC of 0.87 in the ROC curve; cut-off value of 70 μg/L). Specificity was highest if using serial NSE measurements at all three time points. These results could be validated in an external cohort of 64 patients.
CONCLUSION
In post-CPR patients on ECMO, NSE can be used to assess the neurologic outcome. Importantly, specificity was highest if using serial NSE measurements. Further research using prospective datasets is needed to verify these findings.

Identifiants

pubmed: 30654013
pii: S0300-9572(18)31032-3
doi: 10.1016/j.resuscitation.2019.01.011
pii:
doi:

Substances chimiques

Biomarkers 0
Phosphopyruvate Hydratase EC 4.2.1.11

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

14-20

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Benedikt Schrage (B)

Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany.

Nicole Rübsamen (N)

Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany.

Peter Moritz Becher (PM)

Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany.

Kevin Roedl (K)

Department of Intensive Care Medicine, University Clinic Hamburg Eppendorf, Hamburg, Germany.

Gerold Söffker (G)

Department of Intensive Care Medicine, University Clinic Hamburg Eppendorf, Hamburg, Germany.

Michael Schwarzl (M)

Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany.

Ansgar Dreher (A)

Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany.

Jury Schewel (J)

Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany.

Alexander Ghanem (A)

Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany.

Hanno Grahn (H)

Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany.

Edith Lubos (E)

Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany.

Alexander Bernhardt (A)

Department of Cardiovascular Surgery, University Heart Center Hamburg Eppendorf, Hamburg, Germany.

Stefan Kluge (S)

Department of Intensive Care Medicine, University Clinic Hamburg Eppendorf, Hamburg, Germany.

Hermann Reichenspurner (H)

Department of Cardiovascular Surgery, University Heart Center Hamburg Eppendorf, Hamburg, Germany.

Stefan Blankenberg (S)

Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany.

Tobias Spangenberg (T)

Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany.

Dirk Westermann (D)

Department of General and Interventional Cardiology, University Heart Center Hamburg Eppendorf, Hamburg, Germany. Electronic address: d.westermann@uke.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH